Athena Athena

X
[{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indications of Refractory Pemphigus Vulgaris and Pemphigus Foliaceus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-CD20 Monoclonal Antibody Rituxan Approved for the Prevention of Recurrence of Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"ASLAN Pharmaceuticals","pharmaFlowCategory":"D","amount":"$138.5 million","upfrontCash":"$12.0 million","newsHeadline":"ASLAN Pharmaceuticals Enters into a Strategic Licensing Deal with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-CD20 Monoclonal Antibody Rituxan\u00ae Approved for Lupus Nephritis that has Not Responded Sufficiently to Existing Therapies","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Zenyaku Kogyo

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Rituxan (rituximab) is an anti-CD20 monoclonal antibody that specifically binds to CD20, a protein expressed on B cells, excluding hematopoietic stem cells and plasma cells, which is used for the treatment of Lupus Nephritis.

            Lead Product(s): Rituximab

            Therapeutic Area: Nephrology Product Name: Rituxan

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Chugai Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 23, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Zenyaku gains exclusive rights to develop and commercialize ASLAN004 (eblasakimab), a potential first-in-class monoclonal antibody targeting the IL‑13 receptor subunit, in atopic dermatitis (AD) and all other indications in Japan.

            Lead Product(s): Eblasakimab

            Therapeutic Area: Dermatology Product Name: ASLAN004

            Highest Development Status: Phase II Product Type: Large molecule

            Recipient: ASLAN Pharmaceuticals

            Deal Size: $138.5 million Upfront Cash: $12.0 million

            Deal Type: Licensing Agreement June 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Rituxan (rituximab) is an anti-CD20 monoclonal antibody that specifically binds to CD20, a protein expressed on B cells, excluding stem cells and plasma cells. It attacks target B cells using the immune system equipped with the human body, and damages cells.

            Lead Product(s): Rituximab

            Therapeutic Area: Rare Diseases and Disorders Product Name: Rituxan

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Chugai Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 20, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Rituxan, an anti-CD20 monoclonal antibody got approval in additional indications of refractory pemphigus vulgaris and pemphigus foliaceus by MHLW based on results of investigator-initiated phase II clinical trial in Japan of KCTR-D006 study and PEMPHIX study.

            Lead Product(s): Rituximab

            Therapeutic Area: Immunology Product Name: Rituxan

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Chugai Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 24, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY